Literature DB >> 34877661

Semiparametric additive time-varying coefficients model for longitudinal data with censored time origin.

Yanqing Sun1, Qiong Shou2, Peter B Gilbert3,4, Fei Heng5, Xiyuan Qian6.   

Abstract

Statistical analysis of longitudinal data often involves modeling treatment effects on clinically relevant longitudinal biomarkers since an initial event (the time origin). In some studies including preventive HIV vaccine efficacy trials, some participants have biomarkers measured starting at the time origin, whereas others have biomarkers measured starting later with the time origin unknown. The semiparametric additive time-varying coefficient model is investigated where the effects of some covariates vary nonparametrically with time while the effects of others remain constant. Weighted profile least squares estimators coupled with kernel smoothing are developed. The method uses the expectation maximization approach to deal with the censored time origin. The Kaplan-Meier estimator and other failure time regression models such as the Cox model can be utilized to estimate the distribution and the conditional distribution of left censored event time related to the censored time origin. Asymptotic properties of the parametric and nonparametric estimators and consistent asymptotic variance estimators are derived. A two-stage estimation procedure for choosing weight is proposed to improve estimation efficiency. Numerical simulations are conducted to examine finite sample properties of the proposed estimators. The simulation results show that the theory and methods work well. The efficiency gain of the two-stage estimation procedure depends on the distribution of the longitudinal error processes. The method is applied to analyze data from the Merck 023/HVTN 502 Step HIV vaccine study.
© 2021 The International Biometric Society.

Entities:  

Keywords:  Step vaccine trial; censored time origin; kernel smoothing; longitudinal data; random sampling times; weight selection

Year:  2021        PMID: 34877661      PMCID: PMC9275555          DOI: 10.1111/biom.13610

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   1.701


  17 in total

1.  Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.

Authors:  Bryan E Shepherd; Peter B Gilbert; Yannis Jemiai; Andrea Rotnitzky
Journal:  Biometrics       Date:  2006-06       Impact factor: 2.571

2.  Analysis of Longitudinal Data with Semiparametric Estimation of Covariance Function.

Authors:  Jianqing Fan; Tao Huang; Runze Li
Journal:  J Am Stat Assoc       Date:  2007-06-01       Impact factor: 5.033

3.  Profile local linear estimation of generalized semiparametric regression model for longitudinal data.

Authors:  Yanqing Sun; Liuquan Sun; Jie Zhou
Journal:  Lifetime Data Anal       Date:  2013-03-08       Impact factor: 1.588

4.  An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study).

Authors:  D W Fitzgerald; H Janes; M Robertson; R Coombs; I Frank; P Gilbert; M Loufty; D Mehrotra; A Duerr
Journal:  J Infect Dis       Date:  2011-03-15       Impact factor: 5.226

5.  Generalized semiparametric varying-coefficient model for longitudinal data with applications to adaptive treatment randomizations.

Authors:  Li Qi; Yanqing Sun; Peter B Gilbert
Journal:  Biometrics       Date:  2016-12-05       Impact factor: 2.571

6.  Estimating time since infection in early homogeneous HIV-1 samples using a poisson model.

Authors:  Elena E Giorgi; Bob Funkhouser; Gayathri Athreya; Alan S Perelson; Bette T Korber; Tanmoy Bhattacharya
Journal:  BMC Bioinformatics       Date:  2010-10-25       Impact factor: 3.169

7.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

8.  Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).

Authors:  Ann Duerr; Yunda Huang; Susan Buchbinder; Robert W Coombs; Jorge Sanchez; Carlos del Rio; Martin Casapia; Steven Santiago; Peter Gilbert; Lawrence Corey; Michael N Robertson
Journal:  J Infect Dis       Date:  2012-05-04       Impact factor: 5.226

9.  Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment.

Authors:  Raabya Rossenkhan; Morgane Rolland; Jan P L Labuschagne; Roux-Cil Ferreira; Craig A Magaret; Lindsay N Carpp; Frederick A Matsen Iv; Yunda Huang; Erika E Rudnicki; Yuanyuan Zhang; Nonkululeko Ndabambi; Murray Logan; Ted Holzman; Melissa-Rose Abrahams; Colin Anthony; Sodsai Tovanabutra; Christopher Warth; Gordon Botha; David Matten; Sorachai Nitayaphan; Hannah Kibuuka; Fred K Sawe; Denis Chopera; Leigh Anne Eller; Simon Travers; Merlin L Robb; Carolyn Williamson; Peter B Gilbert; Paul T Edlefsen
Journal:  Viruses       Date:  2019-07-03       Impact factor: 5.048

10.  HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders.

Authors:  Holly Janes; Joshua T Herbeck; Sodsai Tovanabutra; Rasmi Thomas; Nicole Frahm; Ann Duerr; John Hural; Lawrence Corey; Steve G Self; Susan P Buchbinder; M Juliana McElrath; Robert J O'Connell; Robert M Paris; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttihum; Jaranit Kaewkungwal; Merlin L Robb; Nelson L Michael; James I Mullins; Jerome H Kim; Peter B Gilbert; Morgane Rolland
Journal:  Nat Med       Date:  2015-08-31       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.